NanoViricides, Inc. to Present Anti-Influenza Drug Candidate FluCide Studies at the Influenza Congress 2009

WEST HAVEN, Conn.--(Business Wire)--
NanoViricides, Inc. (OTC BB: NNVC.OB) (the "Company"), announced today that the
Company`s CEO, Eugene Seymour, MD, MPH, has been invited to participate in a
panel discussion at the Influenza Congress USA 2009, in Washington DC on
November 19th (www.terrapinn.com/usaflu). The discussion will center on the
"Evolving Role of Anti-Virals" in influenza treatment.

Dr. Seymour will review the Company`s recent in vivo studies against influenza.
The success of these studies has led the Company to consolidate its
anti-influenza drug programs into a single, pan-influenza drug, "FluCide". This
single drug is expected to be highly effective against all forms of influenza A,
including the recent "swine flu" 2009/CA/H1N1 strain, seasonal flu strains, as
well as H5N1 bird flu strains feared to be capable of creating a devastating
pandemic, and other highly pathogenic strains on the horizon.

A "pan-influenza" drug is widely sought in order to enable treating infections
from novel influenza viruses. It is well known that pandemics can be caused by
novel strains of influenza. Fortunately the current "swine flu" H1N1/2009
pandemic is now believed to cause fatality rates comparable to seasonal
influenzas. However, influenza viruses are known to change rapidly. New
influenza viruses are often generated by mixing of genetic material from
existing influenza viruses, known as "reassortments". Such changes can lead to a
novel virus that is capable of causing a wide-spread pandemic accompanied by a
high fatality rate. In addition, mutations are known to have led to influenza
strains resistant to existing anti-influenza drugs. The Company believes that
FluCide is designed to minimize the possibility of resistant mutations.

All of the Company`s anti-influenza studies to date have been conducted by
independent external investigators.

Dr. Seymour will join other industry panelists in the "Evolving Role of
Anti-Virals" session to discuss drug resistance, drug efficacy and clinical
development of anti-viral treatments for influenza. The panelists and
participants include pharmaceutical and biotech decision makers and executives
as well as government and regulatory agency representatives from a number of
countries.

This conference is designed to bring together key stakeholders from the
pharmaceutical and biotech industries, as well as governmental science and
regulatory segments to discuss appropriate responses to the evolving influenza
pandemic, according to the organizers.

About NanoViricides:

NanoViricides, Inc. (www.nanoviricides.com) is a development stage company that
is creating special purpose nanomaterials for viral therapy. The Company's novel
nanoviricide class of drug candidates are designed to specifically attack
enveloped virus particles and to dismantle them. The Company is developing drugs
against a number of viral diseases including H1N1 swine flu, H5N1 bird flu,
seasonal Influenza, HIV, oral and genital Herpes, viral diseases of the eye
including EKC and herpes keratitis, Hepatitis C, Rabies, Dengue fever, and Ebola
virus, among others.

This press release contains forward-looking statements that reflect the
Company's current expectation regarding future events. Actual events could
differ materially and substantially from those projected herein and depend on a
number of factors. Certain statements in this release, and other written or oral
statements made by NanoViricides, Inc. are "forward-looking statements" within
the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the
Securities Exchange Act of 1934. You should not place undue reliance on
forward-looking statements since they involve known and unknown risks,
uncertainties and other factors which are, in some cases, beyond the Company's
control and which could, and likely will, materially affect actual results,
levels of activity, performance or achievements. The Company assumes no
obligation to publicly update or revise these forward-looking statements for any
reason, or to update the reasons actual results could differ materially from
those anticipated in these forward-looking statements, even if new information
becomes available in the future. Important factors that could cause actual
results to differ materially from the company's expectations include, but are
not limited to, those factors that are disclosed under the heading "Risk
Factors" and elsewhere in documents filed by the company from time to time with
the United States Securities and Exchange Commission and other regulatory
authorities. Although it is not possible to predict or identify all such
factors, they may include the following: demonstration and proof of principle in
pre-clinical trials that a nanoviricide is safe and effective; successful
development of our product candidates; our ability to seek and obtain regulatory
approvals, including with respect to the indications we are seeking; the
successful commercialization of our product candidates; and market acceptance of
our products.

NanoViricides, Inc.
Amanda Schuon, 310-550-7200
info@nanoviricides.com

Copyright Business Wire 2009